Evan Morris, Roche
S
Evan Morris
VP, Government Affairs and Public Policy, Roche
SECRET TO SUCCESS: "It's what you know, not who you know"
SECRET: "I'm a crummy golfer"
After training at DC's policy-and-lobbying powerhouse Patton Boggs, self-described "food and drug lawyer" Evan Morris joined Roche—and the industry—in January 2005. Having watched his mom beat breast cancer, he was inspired to play on the pharma team. "That was before FDA became managed through Congress," he says by way of acknowledging his baptism by partisan fire. Morris has led Roche's Washington office in negotiating policy for flu preparedness, hep C access, and Medicare and Medicaid. The just-barely-thirtysomething Morris is already an old hand inside the beltway. A White House intern at 18, he learned a lasting lesson from his boss, the deputy chief of staff: "'Speak truth to power, no matter how powerful the individual or how ugly the truth.' At the end of the day, that's how I want to be known."
Evan Morris
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
